Since hyperglycemia and insulin resistance are characteristics of T2DM, therapeutic agents or inhibitors that reduce postprandial hyperglycemia and hyperinsulinemia and improve insulin sensitivity have been used to treat T2DM [4,5,8]. This evidence concerns the gene INS and type 2 diabetes mellitus.